Skip to Content

Procysbi Delayed Release Dosage

Generic name: Cysteamine bitartrate 25mg
Dosage form: capsule, delayed release pellets

Medically reviewed on January 2, 2018.

Important Dosing Instructions

  • Initiate cysteamine treatment immediately after diagnosis of nephropathic cystinosis.
  • Cysteamine-naïve Patients: Start PROCYSBI at a fraction of the maintenance dosage.
    • Patients 1 year to less than 6 years: Gradually increase the dosage, allowing a minimum of 2 weeks between adjustments [see Dosage and Administration (2.2)].
    • Patients 6 years of age and older: Gradually increase the dosage over 4 to 6 weeks until the maintenance dosage is achieved.
  • Patients switching from immediate-release cysteamine: Start the total daily dosage of PROCYSBI at a dosage equal to the previous total daily dosage of immediate-release cysteamine [see Dosage and Administration (2.3)].
  • If adverse reactions occur, decrease the PROCYSBI dosage.
  • After the maintenance dosage of PROCYSBI is achieved: The dosage may need to be further increased to achieve a therapeutic target WBC cystine concentration. The maximum dosage of PROCYSBI is 1.95 grams/m2 of body surface area per day [see Dosage and Administration (2.4, 2.5)].
  • Round dose calculations to the nearest incremental dosage that can be administered using the available capsule strengths. Only use whole capsules.

Starting and Maintenance Dosing in Cysteamine-Naïve Patients

  • Start treatment with a dosage equal to ⅙ to ¼ of the maintenance dosage.
  • The maintenance dosage after initial dose escalation is 1.3 g/m2 of body surface area per day divided into two doses given every 12 hours. Table 1 shows the recommended starting and maintenance dosages of PROCYSBI, converted from body-surface area to body weight.
    • Patients 1 year to less than 6 years: Increase the dosage in 10% increments to the maintenance dosage, while monitoring WBC cystine concentrations. Allow a minimum of 2 weeks between dosage adjustments [see Dosage and Administration (2.4, 2.5)]. If a patient achieves the therapeutic target WBC cystine concentration at a dosage below the recommended weight-based maintenance dosage, then stop dosage escalation and use the dosage as the patient's maintenance dosage.
    • Patients 6 years of age and older: Gradually increase the dosage over 4 to 6 weeks until the maintenance dosage is achieved.
  • If a patient experiences initial intolerance, temporarily discontinue PROCYSBI and then re-start at a lower dosage and gradually increase dosage.
Table 1: Starting and Maintenance Dosage of PROCYSBI by Body Weight in Cysteamine-Naïve Patients 1 Year of Age and Older (Dosage Rounded Using Available Capsule Strengths)
Weight in kilograms Starting PROCYSBI Dosage in mg every 12 hours, as a Fraction of the Maintenance Dosage Maintenance PROCYSBI Dosage in mg every 12 hours*
⅙ of dosage ¼ of dosage
*
Higher dosages may be required to achieve target therapeutic WBC cystine concentration [see Dosage and Administration (2.4)].
5 or less 25 50 200
6 to 10 50 75 300
11 to 15 75 100 400
16 to 20 100 125 500
21 to 25 100 150 600
26 to 30 125 175 700
31 to 40 125 200 800
41 to 50 150 225 900
51 kg and greater 175 250 1000

Switching Patients from Immediate-Release Cysteamine Bitartrate

  • When switching patients from immediate-release cysteamine bitartrate to PROCYSBI, the starting total daily dose of PROCYSBI is equal to the previous total daily dose of immediate-release cysteamine bitartrate. Divide the total daily dose by two and administer every 12 hours.
  • For patients who may experience temporary intolerance upon starting PROCYSBI, decrease the dosage and then gradually increase to the maintenance dosage.
  • Measure the WBC cystine concentration two weeks after initiation of PROCYSBI [see Dosage and Administration (2.5)]. Adjust the PROCYSBI dosage as needed to achieve the therapeutic target WBC cystine concentration [see Dosage and Administration (2.4)]. The maximum dosage of PROCYSBI is 1.95 grams/m2 per day.

Dosage Titration to Therapeutic Target WBC Cystine Concentration

  • Measure WBC cystine concentration and titrate the PROCYSBI dosage as needed to achieve the therapeutic target WBC cysteine concentration [see Dosage and Administration (2.5)].
  • If the measured WBC cystine concentration is above the target level for cystine depletion, consider the following before dose adjustment: adherence to medication and dosing interval, the timing between the last dose and the blood draw for the laboratory measurement, and the timing of PROCYSBI administration in relation to food or other administration instructions.
  • If a dose adjustment is required, increase the dosage by 10%, rounded to nearest dosage that can be administered using the available capsule strengths. For patients 1 year to less than 6 years of age, allow a minimum of two weeks between dose increments. The maximum dosage of PROCYSBI is 1.95 grams/m2 per day.
  • If adverse reactions occur, decrease the PROCYSBI dosage. Some patients may be unable to achieve their therapeutic target due to poor tolerability of PROCYSBI [see Warnings and Precautions (5), Adverse Reactions (6.1)].

Laboratory Monitoring

  • WBC cystine concentration may be measured using the mixed leukocyte assay or by using assays for specific WBC subsets (e.g., granulocyte method). The methods used for measuring cystine and total protein content may also vary among individual laboratories [see Clinical Pharmacology (12.2)].
  • Normal WBC cystine ranges and therapeutic target levels for cystine depletion depend upon the assay method used by the individual laboratory. WBC cystine values obtained from using different assay methods may not be interchangeable. Refer to the assay-specific therapeutic target for cystine depletion. When using the mixed leukocyte assay, the recommended target WBC cystine concentration is less than 1 nmol ½ cystine/mg protein.
  • The recommended frequency of monitoring WBC cystine concentration is as follows:
    • Cysteamine-naïve patients 1 year to less than 6 years: Obtain measurement two weeks after initiation of PROCYSBI treatment and continue monitoring during dosage titration period until the therapeutic target WBC cystine concentration is achieved. Once the therapeutic target is achieved, continue monitoring monthly for 3 months, then quarterly for 1 year, and then twice-yearly, at a minimum.
    • Cysteamine-naïve patients greater than 6 years: Obtain measurement after reaching the maintenance PROCYSBI dosage, then monthly for 3 months, quarterly for 1 year, and then twice-yearly, at a minimum.
    • Patients switching from immediate-release cysteamine to PROCYSBI: Obtain measurement two weeks after initiation of PROCYSBI treatment and continue monitoring if further dosage titration is required to achieve therapeutic target WBC cystine concentration. Once the therapeutic target is achieved, continue monitoring quarterly for 6 months, then twice yearly, at a minimum.
  • Obtain blood samples for WBC cystine concentration measurement 12 hours after the patient's last PROCYSBI dose, prior to administration of the next dose (i.e., trough concentration). In addition, it is important to accurately record the time of the last dose, the actual dose, and the time the blood sample was taken.

Administration

  • Swallow PROCYSBI capsules whole.
  • Do not crush or chew capsules or capsule contents.
  • Take PROCYSBI capsules with fruit juice (except grapefruit juice) or water.
  • Administer PROCYSBI at least 1 hour before or 1 hour after medications containing bicarbonate or carbonate [see Drug Interactions (7.1)].
  • Do not eat for at least 2 hours before taking PROCYSBI and for at least 30 minutes after to maximize absorption. If patients are unable to take PROCYSBI without eating, take with food and limit the amount of food to approximately 4 ounces (1∕2 cup) within 1 hour before taking PROCYSBI through 1 hour after taking PROCYSBI. Take PROCYSBI in a consistent manner in regard to food. Avoid high fat food close to dosing of PROCYSBI.
  • Avoid drinking alcohol while taking PROCYSBI [see Drug Interactions (7.2)].

For patients who have difficulty swallowing capsules, follow the instructions below for administration with food or liquid. Administration of PROCYSBI with foods and liquids not included below has not been studied clinically and is not recommended.

Administration with Applesauce or Berry Jelly:

  1. Place approximately 4 ounces (1/2 cup) or a smaller amount that can be consumed in one feeding of either applesauce or berry jelly into a clean container.
  2. Open the capsule(s).
  3. Sprinkle the entire capsule contents of intact granules on applesauce or berry jelly.
  4. Mix the granules with the applesauce or berry jelly.
  5. Consume the entire contents within 30 minutes of mixing. Do not chew the granules. Do not save the applesauce or berry jelly and granules for later use.

Administration with Fruit Juice (except grapefruit juice):

  1. Pour approximately 4 ounces (1/2 cup) of fruit juice into a clean cup.
  2. Open the capsule(s).
  3. Sprinkle the intact granules into the juice.
  4. Gently stir until mixed.
  5. Drink the entire contents within 30 minutes of mixing. Do not chew the granules. Do not save the fruit juice and granules mixture for later use.

Administration with Applesauce via a Gastrostomy (G) Tube (14 French or larger)

A bolus (straight) feeding tube is recommended.

  1. Flush the gastrostomy tube button first with 5 mL of water to clear the button.
  2. Open the capsule and empty the granules into a clean container with approximately 4 ounces (1/2 cup) of applesauce. Use only strained applesauce with no chunks. A minimum of 1 ounce (1/8 cup) of applesauce may be used for children 25 kg or less starting PROCYSBI at a dose of 1 or 2 capsules.
  3. Mix the intact granules into the applesauce.
  4. Draw up the mixture into a syringe. Keep the feeding tube horizontal during administration and apply rapid and steady pressure (10 mL/10 seconds) to dispense the syringe contents into the tube within 30 minutes of preparation.
  5. Repeat step 3 until all of the mixture is administered. Do not save the applesauce and granule mixture for later use.
  6. Draw up a minimum of 10 mL of fruit juice or water into another syringe, swirl gently, and flush the tube.

Missed Doses

  • If a dose is missed, take the dose as soon as possible up to 8 hours after the scheduled time. However, if a dose is missed and the next scheduled dose is due in less than 4 hours, do not take the missed dose and take the next dose at the usual scheduled time. Do not take 2 doses at one time to make up for a missed dose.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide